NIH Offers Exclusive License for RXFP1 Agonist Inventions
Published Date: 7/23/2026
Notice
Summary
The National Institutes of Health plans to give Modala Bio an exclusive license to use new RXFP1 agonist inventions that could help treat diseases like cancer, heart failure, and fibrosis. This means Modala Bio gets special rights to develop and sell these promising medicines worldwide. If you want to comment or apply for a license, you have until August 24, 2026, so don’t miss out!
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
Exclusive RXFP1 License to Modala Bio
The National Institutes of Health is contemplating granting Modala Bio an exclusive patent license to novel RXFP1 agonists, with a prospective territory that may be worldwide and a field of use limited to treatments for cancers, cardiovascular, pulmonary, and fibrotic diseases. This exclusive right would give Modala special commercial control over these inventions.
Prospective License Will Be Royalty-Bearing
The notice states the prospective exclusive license to practice the RXFP1 inventions will be royalty-bearing, meaning the licensee would pay royalties to the patent owners or the government under the license terms. This condition applies if the exclusive license is granted.
Deadline to Apply or Comment
If you want to apply for a license or submit comments about the contemplated exclusive license to Modala Bio, your written materials must be received by the National Center for Advancing Translational Sciences on or before August 24, 2026. License applications will be presumed to contain business confidential information, while general comments and objections (not in license applications) may be made publicly available.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20771, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review at the NIH is holding several closed virtual meetings in early November 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, affecting researchers seeking funding. No direct money changes are announced, but these reviews decide who gets research grants.
2026-20705, Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Antibody Specifically Binding to Severe Fever With Thrombocytopenia Syndrome Virus Antigen and Use Thereof
The National Institute of Allergy and Infectious Diseases plans to give Korea National Institute of Health an exclusive license to develop and sell a special antibody that targets a dangerous virus causing severe fever and low platelets. This deal helps speed up turning the invention into real-world treatments. Comments or license requests must be sent by October 26, 2026.
2026-20424, National Cancer Institute; Notice of Meeting
The President's Cancer Panel is holding a free virtual meeting on October 15, 2026, to talk about how GLP-1 medications can help lower cancer risks linked to obesity. Anyone interested can join online or send in comments beforehand. This meeting is a great chance for patients, doctors, and researchers to learn about new ways to fight cancer and improve health.
2026-20365, Center For Scientific Review; Notice of Closed Meetings
The NIH's Center for Scientific Review is holding several closed virtual meetings on October 29-30, 2026, to review and evaluate grant applications. These meetings protect private info and trade secrets while deciding which research projects get funding. Scientists applying for grants in areas like biochemistry, software engineering, and mental health will be affected, with no direct money changes announced but important decisions coming soon.
2026-20151, Notice of NIH Tribal Consultations and Listening Session
The NIH is inviting Tribal leaders and members to join two important meetings and a listening session during the National Congress of American Indians Annual Convention in October 2026. They’ll talk about new health research projects, renewing support for Tribal health centers, and shaping a new Tribal Data Sovereignty Policy. Tribes can also send their thoughts by November 20, 2026, helping shape future health programs and policies.
2026-19719, Center for Scientific Review; Amended Notice of Meeting
The NIH’s Center for Scientific Review is shortening a key meeting from two days to just one day on October 13, 2026, keeping the same 9 a.m. to 6 p.m. hours. This change affects members of the Surgical Sciences and Bioengineering review group and means less time in the room but no public access. No money changes or delays are expected—just a quicker, tighter meeting!
Previous / Next Documents
Previous: 2026-14841, Quarterly Publication of Individuals, Who Have Chosen To Expatriate
Every few months, the IRS shares a list of people who gave up their U.S. citizenship or long-term resident status. This update covers those who lost it by June 30, 2026. If you’re thinking about expatriating, know this process is official, public, and can have tax and timing consequences.
Next: 2026-14855, Intent To Request Extension From OMB of One Current Public Collection of Information: Transportation Security Officer Medical Questionnaire
The TSA is asking to keep using its medical questionnaire for Transportation Security Officer (TSO) candidates to make sure they’re fit for the job. They want to extend this paperwork approval and are inviting the public to share thoughts by September 21, 2026. This won’t cost extra money but helps keep airport security strong and safe!